Pancreatic neuroendocrine tumour

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
N Neurology/Psychiatry (ATC N) 1
ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase II/III: 1 Phase IV: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II/III

1 trial
  • Exelixis Inc. Commercial
    N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- YL)OXY)PHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
    2025-521043-20-00 8 countries 2026 n=172
    Recruiting

Phase IV

1 trial
  • Antwerp University Hospital Academic
    IMP not specified
    2022-502703-30-00 2 countries 2023 n=270
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Exelixis Inc. Commercial 1 Phase II/III 1
Antwerp University Hospital Academic 1 Phase IV 1
New trials by year
2023
1
2026
1
← All indication landscapes